Products
PRIMARY ANTIBODY
SECONDARY ANTIBODY
PROTEIN & PEPTIDES
BIOCHEMICALS
ASSAY & ELISA KITS
LOADING CONTROL
OTHER REAGENTS
SERUMS
CELL LINE
Contact Us
About Us
Login
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Products
Contact Us
About Us
Shopping Cart
Loading....
Login Account
Sign In
Register
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Home
BioChemicals
Tozasertib
tcsc0007
Tozasertib
Order Now
AVAILABLE SIZES
50mg
100mg
250mg
500mg
1g
$
617.00
Add to Cart
ORDERING INFORMATION
International
TAICLONE BIOTECH CORP.
order@taiclone.com
+886-2-2735-9682
+886-2-2735-9807
Data sheet
Download PDF Datasheet
Technical Inquries
Submit Review
Submit Review
Please choose your application, enter the information requested below. * Marked fields are mandatory.
Full Name
Email
Contact Number
Application
Please Select..
Western blot (WB)
Immunohistochemistry (IHC)
Immunofluorescence (IF)
Immunocytochemistry (ICC)
Immunoprecipitation (IP)
Co-Immunoprecipitation (CoIP)
Chromatin Immunoprecipitation (ChIP)
RNA Binding Protein Immunoprecipitation (RIP)
Sample
Loading Amount
Loading Type
UG
CELLS
Treatment
Temperature
Exposure
Observe Band
Fixative
Select One
Acetone
Formaldehyde
Methanol
Paraformaldehyde
Other
Antigen Retrieval
Select One
Heat mediated
Enzymatic
Other
None
Positive Control
Negative Control
Dilution *
1:
Incubation Time *
Select Image *
Choose a file...
Rating *
Remarks *
Submit Review
Product Description
Tozasertib is the inhibitor of
Aurora-A, -B, -C kinases
with
K
i
values of 0.6, 18, 4.6 nM, respectively.
IC50 & Target: Ki: 0.6 nM (Aurora A), 18 nM (Aurora B), 4.6 nM (Aurora C)
[1]
In Vitro:
Tozasertib induces similar cytotoxicity with IC
50
of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. Tozasertib prevents the CAL-62 proliferation in a time-dependent manner. Tozasertib treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with Tozasertib inhibits proliferation with the IC
50
between 25 and 150 nM. The Tozasertib significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that Tozasertib induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to Tozasertib show an accumulation of cells with ≥ 4N DNA content. Time-lapse analysis demonstrates that Tozasertib-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following Tozasertib treatment
[2]
. Tozasertib has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples
[3]
.
Information
CAS No
639089-54-6
Formula
C
23
H
28
N
8
OS
Clinical Information
clinicalinformation
Pathway
Cell Cycle/DNA Damage
Epigenetics
Autophagy
Target
Aurora Kinase
Aurora Kinase
Autophagy
Specifications
Purity / Grade
>98%
Solubility
DMSO : ≥ 106.67 mg/mL (229.60 mM)
Smiles
smiles
Misc Information
Alternative Names
MK-0457;VX 680
Observed Molecular Weight
464.59
related data
Get valuable resources and offers directly to your email.
REGISTER NOW